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Background: Mortality from severe acute respiratory distress syndrome exceeds 40% and there is no available
pharmacologic treatment. Mechanical ventilation contributes to lung dysfunction and mortality by causing ventilator-
induced lung injury. We explored the utility of simvastatin in a mouse model of severe ventilator-induced lung injury.
Methods: Male C57BL6 mice (n = 7/group) were pretreated with simvastatin or saline and received protective
(8 mL/kg) or injurious (25 mL/kg) ventilation for four hours. Three doses of simvastatin (20 mg/kg) or saline were
injected intraperitoneally on days −2, −1 and 0 of the experiment. Lung mechanics, (respiratory system elastance, tissue
damping and airway resistance), were evaluated by forced oscillation technique, while respiratory system compliance
was measured with quasi-static pressure-volume curves. A pathologist blinded to treatment allocation scored
hematoxylin-eosin-stained lung sections for the presence of lung injury. Pulmonary endothelial dysfunction was
ascertained by bronchoalveolar lavage protein content and lung tissue expression of endothelial junctional protein
Vascular Endothelial cadherin by immunoblotting. To assess the inflammatory response in the lung, we determined
bronchoalveolar lavage fluid total cell content and neutrophil fraction by microscopy and staining in addition to
Matrix-Metalloprotease-9 by ELISA. For the systemic response, we obtained plasma levels of Tumor Necrosis Factor-α,
Interleukin-6 and Matrix-Metalloprotease-9 by ELISA. Statistical hypothesis testing was undertaken using one-way
analysis of variance and Tukey’s post hoc tests.
Results: Ventilation with high tidal volume (HVt) resulted in significantly increased lung elastance by 3-fold and
decreased lung compliance by 45% compared to low tidal volume (LVt) but simvastatin abrogated lung mechanical
alterations of HVt. Histologic lung injury score increased four-fold by HVt but not in simvastatin-pretreated mice. Lavage
pleocytosis and neutrophilia were induced by HVt but were significantly attenuated by simvastatin. Microvascular
protein permeability increase 20-fold by injurious ventilation but only 4-fold with simvastatin. There was a 3-fold
increase in plasma Tumor Necrosis Factor-α, a 7-fold increase in plasma Interleukin-6 and a 20-fold increase in lavage
fluid Matrix-Metalloprotease-9 by HVt but simvastatin reduced these levels to control. Lung tissue vascular endothelial
cadherin expression was significantly reduced by injurious ventilation but remained preserved by simvastatin.
Conclusion: High-dose simvastatin prevents experimental hyperinflation lung injury by angioprotective and
anti-inflammatory effects.
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Non-cardiogenic pulmonary edema, known as Acute Re-
spiratory Distress Syndrome (ARDS), is a frequent cause
of respiratory failure [1]. There are multiple etiologies
but the final result is airspace flooding with protein-rich
edema due to a leaky and inflamed alveolo-capillary mem-
brane. Mechanical ventilation may exacerbate edema
and inflammation by alveolar over-distention (ventilator-
induced lung injury -VILI) and, consequently, ventilation
with low tidal volume (Vt) is now routinely used [2]. Des-
pite optimal ventilation, several patients with severe lung
injury will remain with high inflation pressures and poor
oxygenation, facing a mortality risk in excess of 40% [3].
In searching for promising medical therapies for
ARDS, we previously showed that pre-treatment with
atorvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitor (“statin”) can abrogate VILI in iso-
lated rabbit lungs [4]. Given the limited significance of
immune cells in this model, the atorvastatin effect likely
comprised pre-conditioning of resident lung cells to
withstand stretch injury, rather than modifying the im-
mune response. Even though the drug almost com-
pletely eliminated lung injury in the ex vivo model, its
effect cannot be extrapolated in the intact animal. In
this work, we expand upon this observation using an
in vivo mouse model of aggressive VILI with high-dose
simvastatin pre-treatment. Statins attract research inter-
est for this indication due to their pleiotropic immuno-
modulating and endothelial-protective properties [5].
Effects specific to the endothelium, which may help pre-
serve the endothelial barrier in the setting of inflamma-
tion, include modulating cytoskeletal rearrangement
events, attenuating oxidative burst and improving nitric
oxide bioavailability [5]. Accordingly, there is a number
of reports demonstrating clear benefit in pre-clinical
lung injury elicited by endotoxin, radiation, and mech-
anical ventilation [6-8], while a partial effect was seen in
bacterial pneumonia models [9-11] and no effect was
seen in viral pneumonia models [12,13].
In translational studies, simvastatin given to patients
with ARDS did not improve mortality, but had a signi-
ficant effect on extrapulmonary organ dysfunction and
a trend towards improvement of pulmonary outcomes
[14]. In contrast, in patients with ventilator-associated
pneumonia, who were overwhelmingly on statins prior
to ICU admission, Papazian et al. found no improve-
ment in survival or other relevant outcomes [15]. In a
more recent trial in sepsis patients with ARDS, rosuvas-
tatin treatment early into the disease process did not
alter any of the clinical outcomes studied [16]. However,
relatively few of these patients had severe ARDS [3],
which is associated with the highest mortality. Thus, an
important subpopulation of ARDS patients may have
been understudied. Even more recently, McAuley et al.administered simvastatin to a patient population of mo-
derate to severe ARDS but again a clinical impact failed
to be demonstrated [17].
Mechanical ventilation is almost universally applied as
a means of support for patients with ARDS but can pro-
voke further lung dysfunction. The predominant mech-
anism is alveolar over-distention (volutrauma) [2], which
elicits an acute response with local and systemic impact
[2]. In ARDS patients this may occur despite use of low
Vt, due to preexisting airspace collapse from edema and
atelectasis. To elicit VILI in healthy mice, however, ven-
tilation with supra-normal Vt is required. We have pre-
viously found that ventilation with a Vt of 25 mL/Kg
for four hours causes robust increase in lung tissue elas-
tance coefficient, in parallel with pulmonary micro-
vascular permeability [18,19]. We now hypothesize that
pre-treatment with simvastatin in vivo preserves pul-
monary vascular integrity and lung mechanics in response
to tidal stretch. Using a high Vt ventilation protocol we
elicited lung injury and measured lung function in
addition to morphological and biochemical parameters of




C57BL/6 mice were bred and maintained in the animal
facilities of the “Hellenic Pasteur Institute” (Athens,
Greece) under specific pathogen–free conditions. Mice
were housed at 20–22°C, with 55 ± 5% humidity, a 12-
hour light–dark cycle and unrestricted access to food
and water. All experimentation was approved by the
Evangelismos hospital Research Review Board as well as
by the Veterinary Service of the governmental prefecture
of Attica. Daily Simvastatin (20 mg/kg, Sigma) or normal
saline (NS) intraperitoneal (ip) administration started
2 days prior to the experiment with the final dose applied
1 hour prior to mechanical ventilation. Simvastatin was
dissolved in pure ethanol and the stock solution was di-
luted in NS to a mean volume of 50 μL per injection.
Experimental design
Mice were randomly assigned to four groups, each com-
prising 7 animals (n = 7). Control groups were pre-treated
with simvastatin or NS and were ventilated with ambient
air at low tidal volume (LVt) of 8 mL/kg and respiratory
rate of 150 breaths/min. Injury groups were pre-treated
with simvastatin or NS and were ventilated with ambient
air using high tidal volume (HVt) of 25 mL/kg and re-
spiratory rate of 50 breaths/min.
Mechanical ventilation
Anesthesia was induced by ketamine/xylazine (100 mg/Kg,
10 mg/Kg respectively) injected ip 1 hour after the final
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administering 1/3 of the initial dose every 45 min. The
trachea was exposed under sterile conditions, cannu-
lated with a 22-gauge catheter and sutured. Mechanical
Ventilation was performed using a small animal ventilator
(Flexivent, Scireq, Ontario, Canada) and ambient air. Posi-
tive end-expiratory pressure was set at 2 cmH2O and Vt
was set at 8 mL/kg. After an initial 5 min run-in period,
two deep inflations to total lung capacity were applied in
order to standardize lung volume history, followed by a
3-minute LVt ventilation period at the end of which
baseline measurements of lung function were obtained.
We then proceeded to LVt or HVt ventilation accord-
ing to experimental design. Respiratory mechanics were
evaluated by measuring tissue elastance coefficient (H)
and tissue damping coefficient (G) via forced oscillation
technique. Five successive measurements were obtained
in 30- second intervals. Following these maneuvers, a
single quasi-static pressure-volume curve was trans-
duced in order to measure the compliance (Cst) of the
respiratory system [18].Samples
Following mechanical ventilation and lung function
measurement, mice were sacrificed by exsanguination
under deep anesthesia after drawing 400-500 μL of ven-
ous blood from the inferior vena cava in heparinized
27 g syringe. Plasma was separated by centrifugation at
1500xg for 15 min at 4°C and stored at −80°C. Bron-
choalveolar lavage fluid (BALF) was sampled by inject-
ing and slowly withdrawing 1 mL of phosphate-buffered
saline (PBS) through the tracheal cannula three times.
The three aliquots were pooled, centrifuged at 1500×g
for 5 minutes at 4°C and supernatants were stored
at −80°C, while cell pellets were reconstituted in 1 mL
PBS for cell quantification and preparation of cytocentri-
fugation slides.
The lungs were exposed by a midthoracotomy inci-
sion and the pulmonary arteries were perfused with
PBS. The right lung was ligated at the right hilum,
resected, rinsed in PBS, flash-frozen in liquid nitrogen
and stored at −80°C until further analysis. The left lung
was inflated with 4% neutral buffered paraformaldehyde
instilled at 25 cm H2O pressure through the trachea for
120 min. The trachea was tied and the lung was im-
mersed in 4% buffered paraformaldehyde for 24 hours
before a graded alcohol dehydration procedure and em-
bedding in paraffin.BALF total protein
Total protein concentration in the BALF was deter-
mined with the Bio-Rad Dc Protein Assay kit (Bio-Rad
Laboratories, Hercules, CA, USA).Lung tissue histology
4-μm sections of paraffin-embedded tissues were pre-
pared using a microtome (Leica RM2145). Hematoxylin/
eosin-stained lung slides were evaluated by a histopath-
ologist blinded to treatment allocation using a scale from
0 to 4 to determine the degree of interstitial inflamma-
tion, alveolar inflammation and alveolar septal conges-
tion [20]. Four non-sequential sections were evaluated.BALF total cell count and differentiation
Total cell counting in the BALF was performed manu-
ally using an improved Neubauer hemocytometer ac-
cording to standard procedure. To determine BALF cell
type, 50x103 cells were plated and spun on glass slides
by cytocentrifugation at 500xg for 6 min, air-dried and
stained according to May-Gruenwald-Giemsa. Differen-
tial cell count was performed using an optical micro-
scope (OLYMPUS BX50).SDS-polyacrylamide Gel electrophoresis (PAGE)
SDS-PAGE was performed using 12% polyacrylamide
slab gels on a Biorad Mini Protean II electrophoresis
apparatus (Bio-Rad, Hercules, CA, USA). Electrophoresis
was carried out at 120 V for 90 min at ambient tem-
perature. Following electrophoresis, samples were trans-
ferred onto an Immobilon-P PVDF membrane (Millipore,
0.45 μl pore size, Millipore Corporation, Billerica, MA,
USA). Western transfer was performed on a wet transfer
apparatus (Bio-Rad, Hercules, CA, USA). Immuno-
logical detection of Vascular Endothelial (VE)-cadherin
and β-tubulin was performed with antibodies purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA). The final results visualized by enhanced chemi-
luminescence (PerkinElmer, Inc., Waltham, MA, USA)
were developed on Agfa Ortho CP-G Plus films (Agfa
HealthCare NV, Mortsel, Belgium). The density of each
band was expressed in arbitrary units using β-tubulin
as reference.Enzyme-linked immunosorbent assay (ELISA)
Tumor Necrosis Factor-α (TNF-α), interleukin-6 (IL-6)
and matrix metalloproteinase-9 (MMP-9) were measured
in plasma or BALF using ELISA kit (R&D Systems,
Inc., Minneapolis, USA) according to the manufacturers’
instructions.Statistical analysis
Data are presented as mean (±SEM). Statistical hypoth-
esis testing was undertaken by one- or two-way ANOVA
followed by Bonferonni’s or Tukey’s post hoc tests re-
spectively (Graph- Pad Prism, Graph-Pad Software, San
Diego, Calif;). p < 0.05 was considered significant.
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Simvastatin preserves respiratory function in VILI
Decreased lung compliance leading to increased work of
breathing [21] can provoke respiratory failure in ARDS.
Using a high-stretch ventilation protocol, we observed
time-dependent lung mechanics alterations starting to
trend at the 2 hr time-point and reaching significance at
4 hours, while no significant changes to baseline were
recorded with LVt ventilation (Figure 1). Specifically, elas-
tance coefficient H peaked at 62.69±10.36 cmH2O/mL
with baseline values at 31.24±0.91 cmH2O/mL (Figure 1B),
while tissue damping coefficient increased by 1.87-fold at
8.34±1.2 cmH2O/mL compared to baseline (Figure 1D).
To corroborate the above, quasi-static lung compliance,
the reciprocal of elastance, was measured by pressure-
volume curve and was reduced by approx. 45% in the
HVt group compared to LVt ventilation (Figure 1A). In
addition, we recorded a mild but measurable increase inFigure 1 Lung mechanics in ventilator injury. Time-course of lung mech
or low (8 mL/Kg) tidal volume for four hours with simvastatin or saline pre-tre
pressure-volume curve (A) while Lung Tissue Elastance coefficient H (B), Airw
evaluated via forced oscillation technique. (NS: normal saline; Simva: SimvastaNewtonian airway resistance in the HVt group compared
to LVt (Figure 1C). Pre-treatment with simvastatin com-
pletely abrogated all mechanical derangements and pre-
served lung function to the levels recorded at baseline
(Figure 1).
Histological alterations in ventilated lungs are prevented
by simvastatin
We evaluated pulmonary effects of mechanical ventilation
on hematoxylin-eosin-stained lung sections (Figure 2).
Mouse lungs ventilated with LVt for 4 hours presented
normal micromorphology. In contrast, HVt ventilation re-
sulted in leukocyte infiltration, edema and alveolar wall
thickening consistent with acute lung injury (Figure 2A).
The latter is reflected in the increased lung injury values
scored for the HVt untreated group (Figure 2B). Simva-
statin minimized histological changes in HVt-treated
lungs, thus keeping lung injury scores close to baseline.anical alterations in mice undergoing ventilation with high (25 mL/Kg)
atment. Static Compliance Cst was evaluated by a single quasi-static
ay Resistance Rn (C), and Lung Tissue Impedance coefficient G (D) were
tin; *denotes p < 0.05; **p < 0.01 and ***p < 0.001).
Figure 2 Lung tissue histology. (A). Representative hematoxylin-eosin-stained mouse lung sections following high or low tidal volume (Vt)
ventilation with simvastatin or normal saline. (B) Semiquantitative lung injury score comprising interstitial inflammation, alveolar inflammation and
alveolar septal congestion [20]. (NS: normal saline; Simva: Simvastatin; *denotes p < 0.05; **p < 0.01 and ***p < 0.001).
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To assess the lung’s inflammatory response to stretch we
measured BALF cell count, differential and levels of
matrix metaloprotease-9, which is secreted primarily by
neutrophils (Figure 3). We found a modest but signifi-
cant increase in airspace total cell number after 4 hours
of injurious ventilation in placebo-treated mice com-
pared to LVt –ventilated animals. In contrast, BALF total
cell numbers did not rise in simvastatin pre-treated mice
subjected to HVt (Figure 3A). Neutrophils in BALF be-
haved in a manner similar to total cell counts (Figure 3B).
We then performed ELISA to measure levels of MMP-9,
a neutrophil-derived protease known to be involved in
murine and human lung injury. Ventilation with HVt
induced an approximately 60-fold increase in BALF
MMP-9 levels (Figure 3C), which was partly prevented
by simvastatin. Notably, plasma MMP-9 levels did not
rise in response to HVt (data not shown).
Systemic inflammation is attenuated by simvastatin
To assess for potential systemic effects of our model as a
marker of severity, we measured plasma levels of inflam-
matory cytokines TNF-α and IL-6 by ELISA (Figure 4A,B).
High-stretch ventilation led to a 3-fold increase in plasma
TNF-α level and a 7-fold increase in plasma IL-6 level
compared to LVt. Pre-treatment with simvastatin sup-
pressed systemic inflammation and kept the levels of both
cytokines close to the control group.
Simvastatin effects on vascular integrity
Pulmonary edema formation in ARDS relies on increased
microvascular permeability as a result of disruption ofinter-endothelial junctions comprising tight and adherens
junctions. We determined BALF total protein concentra-
tion to probe the structural integrity of the endothelial
barrier in the VILI model (Figure 5A). We observed exces-
sive protein accumulation in the alveolar space in mice
subjected to HVt ventilation. Simvastatin pre-treatment
resulted in a 3-fold decrease in BALF protein compared to
the sham-treated HVt group, without influencing BALF
protein in LVt animals. We then examined protein expres-
sion of VE-cadherin, the structural protein of adherens
junctions (Figure 5B,C). Ventilation with HVt led to a
significant decrease in VE-cadherin levels in lung homoge-
nates by immunoblotting, with or without the presence of
simvastatin.
Discussion
We report that high-dose simvastatin pre-treatment can
prevent lung injury and rescue pulmonary endothelial
dysfunction in a mouse model of mechanical ventilation
with supra-normal inflation volume. Excessive stretch
can be imposed on the alveolo-capillary membrane dur-
ing a tidal inflation when the applied Vt is dispropor-
tionate to the aerated lung volume. Despite widespread
use of “lung protective” ventilation with low Vt, this
situation can still take place in the setting of collapsed
lung and high PEEP in ARDS patients [2]. Since low Vt
ventilation carries the risk of hypercapnea, its use may
be contraindicated altogether in pregnancy or intracranial
hypertension. In several cases of refractory hypoxemia
despite conventional therapy including prone positioning,
extracorporeal oxygenation may be of benefit, although
this treatment is feasible in a highly selected patient group
Figure 4 Proinflammatory cytokines in systemic circulation of ventilated mice. Levels of TNF-α (A) and IL-6 (B) were evaluated via ELISA in
plasma of mice subjected to low tidal volume (LVt) or high tidal volume (HVt) mechanical ventilation for four hours. (NS: normal saline; Simva:
Simvastatin; *denotes p < 0.05; **p < 0.01 and ***p < 0.001).
Figure 3 Effects of simvastatin treatment on airspace inflammation. (A) Total cell counts in broncho-alveolar lavage fluid (BALF) after 4 hours
of mechanical ventilation. (B) Neutrophil fraction expressed as percent of total cells in BALF. (C) Quantification of matrix metalloproteinases −9 by
ELISA in BALF samples of ventilated mice. (LVt: low tidal volume; HVt: high tidal volume; NS: normal saline; Simva: Simvastatin; *denotes p < 0.05;
**p < 0.01 and ***p < 0.001).
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Figure 5 Effect of simvastatin on endothelial dysfunction in experimental ventilator lung inury. (A) Total protein content in BALF was
used as a marker of endothelial barrier disruption by high-tidal-volume ventilation for four hours. (B) Representative immunoblotting of Vascular
Endothelial (VE)-Cadherin, the structural protein of endothelial adherens junctions, in mouse lung tissue. (C) Quantification of intensity ratio of
VE-Cadherin in reference to β-tubulin in lung samples. (LVt: low tidal volume; HVt: high tidal volume; NS: normal saline; Simva: Simvastatin;
*denotes p < 0.05; **p < 0.01 and ***p < 0.001).
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when one considers the potential impact of VILI on mor-
bidity and mortality, the need for a pharmacologic treat-
ment becomes obvious.
Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitor, has been shown to have a number of
endothelial-protective and immunomodulating effects and
has thus been proposed as an interesting investigational
agent for ARDS. Simvastatin pre-treatment in experi-
mental animals has been beneficial in various lung injury
models including endotoxin administration, radiation lung
injury, allergic asthma and bleomycin-induced fibrosis
[6,7,22-24]. Although a number of putative mechanisms
acting both on the endothelium and the innate immune
system have been suggested, few studies have put these to
rigorous testing. Using a model of multisystem inflamma-
tion, Rinaldi et al. reported that simvastatin pre-treatment
in mice induces peroxisome proliferator-activated recep-
tor alpha (PPAR-alpha), which suppresses transcription
of pro-inflammatory genes [25]. The relevance of this
pathway was demonstrated by the fact that simvastatin
protection was lost in PPAR-alpha gene-disrupted mice.Anti-inflammatory effects of statins were also docu-
mented by Zhang et al. [26], who showed a reduction
in neutrophil infiltration to the lung in response to chal-
lenge with streptococcal antigen M1 due to decreased
production of CXC chemokines. Focusing on the endothe-
lium, Chen et al. found that simvastatin induced integrin
β4 expression, which could have an effect on endothelial
barrier stability and signaling [27]. The plethora of desir-
able actions of statins spanning the endothelium and pos-
sibly epithelium of the lung along with the innate immune
system is what makes these drugs so interesting in the
treatment of ARDS.
In our model, ventilation of mice with 25 mL/Kg leads
to a fairly rapid and time-dependent increase in pulmon-
ary vascular permeability coupled to increased lung elas-
tance resulting from fluid accumulation and surfactant
depletion. There is also a moderate inflammatory response
in the alveolar space, manifest as BALF total cell and neu-
trophil accumulation. Neutrophils are phagocytic but also
secretory cells and their products, including oxidants and
protelolytic enzymes, cause tissue destruction. In this
context, we detected a very robust increase of MMP-9
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of extracellular matrix components (e.g. collagen), and
they are involved in both physiological (embryogenesis)
and pathological processes (ARDS [28], bronchial asthma
[29]). MMP-9 is produced in several types of inflamma-
tory cells in response to cyclic mechanical stretch, in-
cluding neutrophils and alveolar macrophages [30,31].
Moreover, inhibition of MMP-9 dampens neutrophil-
mediated inflammation [32] and protects against the
development of VILI. These findings imply a role of
MMP-9 in fostering microvascular membrane failure in
ARDS. The dramatic reduction in MMP-9 seen with
simvastatin pre-treatment attests to the unambiguous
protective effect of the drug in this particular disorder.
Since no rise in systemic levels was found in our mice,
passive leak of MMP-9 from the bloodstream into the
alveolar space is improbable and argues for local gener-
ation. Finally, the rise in plasma cytokines indicates a
systemic component to the inflammatory response as
well, which was also abrogated by simvastatin.
Microvascular barrier failure is documented by the
presence of protein-enriched BALF in mice ventilated
with HVt. Permeability edema is widely accepted to arise
from weakening of inter-endothelial and inter-epithelial
adhesion structures, comprising adherens and tight junc-
tions. Disruption of cell-matrix contact and basal mem-
brane integrity is probably also contributory. However,
how this process unfolds from a mechanistic standpoint
is incompletely understood. In this study, we are among
the first to provide evidence for a reduction in levels of
VE-cadherin by injurious ventilation. Since VE-cadherin
is the main structural component of adherens junctions
[33], loss of VE-cadherin is expected to compromise
endothelial continuity and promote vascular leak. The
mechanism behind the decrement in VE-cadherin could
have implications on our understanding of permeability
edema. Potential explanations include repression of VE-
cadherin expression, protein breakdown by proteases or
enhanced turnover.
As described in our previous study in isolated lungs
[4], pretreatment with statins had a dramatic effect on
lung injury from high-stretch ventilation with almost
complete protection. This seems to be a class-specific ef-
fect, as it was observed with both atorvastatin in the ex-
vivo rabbit model and simvastatin in the in vivo mouse
model. Similar results were presented in a prior study by
Mueller et al. using a mouse model of ventilation with a
Vt of 12 mL/Kg. The authors reported that mechanical
ventilation induced simvastatin-sensitive microstructural
changes on the pulmonary endothelium, consisting of
reduction of the number of caveolae, cell-membrane in-
vaginations responsible for transendothelial transport of
macromolecules and cell-signaling processes. Our pre-
sent study adds to the previous observation using a VILImodel of at least twice the severity. The almost complete
protection afforded to animals by the study agent under-
scores the potential role of statins as a useful adjunct to
the treatment of ARDS. Why is it then that human trials
have been met with such dismal failure? Although we can-
not be sure, we may speculate that one possibility could
be that the doses used are not sufficiently high. Although
no major undesirable effects have been demonstrated with
the doses used in clinical trials, one would wonder whe-
ther higher doses could provide a more robust effect, if
tolerated. Changing the route of administration could also
be of value, e.g. choosing inhaled vs. enteral. Finally, one
major drawback of all clinical research in ARDS is its etio-
logical variability, which precludes the formation of homo-
geneous patient samples and thus therapeutic effects of
drugs on specific patient populations may be missed.
Conclusion
In conclusion, we show that high-dose simvastatin pre-
treatment can preserve lung function by preventing in-
flammation and microvascular dysfunction in a mouse
model of severe ventilator injury. Statins may be clini-
cally useful in minimizing the noxious effects of mecha-
nical ventilation in patients with acute lung injury and
the acute respiratory distress syndrome.
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